Navigation Links
Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $5 million for research to successfully translate neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson's disease. The funding will be awarded under a new Directed LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative.

The Foundation's intention is to identify and drive ambitious projects with a clear plan for accelerating trophic factor therapy through the stages of preclinical and clinical development up to and including Phase 2 clinical studies. Also of interest are therapeutic approaches that include evidence that the trophic factor being studied holds potential for neuroregeneration (helping the brain rejuvenate sick cells) and not merely neuroprotection (protecting existing neurons from death).

Neurotrophic factors (also known as trophic factors or growth factors) are specialized proteins that protect and nourish neurons in the brain, including the dopamine neurons that die in Parkinson's disease. They are a high-priority therapeutic target for MJFF, which has committed approximately $20 million to their development to date, because they have shown potential to slow or stop the progression of Parkinson's in the brain -- something no currently available treatment has been proven to do.

In the last several years, preclinical studies and several early-phase clinical trials in neurotrophic factors have shown promise to revolutionize the treatment of PD. Research increasingly indicates that trophics are safe for use in people, and several Phase 1 neurotrophic clinical trials have shown signs of efficacy. But results from all previous trials have been ultimately inconclusive, and no trophic-based approach has yet been demonstrated to be both safe and efficacious in a Phase 2 clinica
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... April 14, 2014 Popular web information on ... to read and doesn,t address the appropriate risks to ... Medical Center gastroenterologists suggests. , In a review of ... education materials for colorectal cancer screening were written beyond ... sites failed to address key risks, as well as ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... Ohio Heart patients with beliefs about health that ... skip sessions of cardiac rehabilitation, new research suggests. , ... of these beliefs referred to as "irrational health ... was associated with lower adherence to a prescribed cardiac ... Doubting the preventive power of the flu vaccine or ...
(Date:4/14/2014)... high-risk bladder cancer, chemotherapy before or after surgery ... The findings are published early online in ... Cancer Society. , Clinical trials have shown that ... cancer who are given chemotherapy before surgery. There ... also improves survival. To investigate the use of ...
Breaking Medicine News(10 mins):Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... , FERNDALE, Mich. and NEW YORK, Aug. ... today the acquisition of PRESCRIBED solutions [CUSTOMIZED SKINCARE]. Since ... among top dermatologists and plastic surgeons with its innovative, customizable ... product Stop the Clock(TM) Triple Action Anti-aging Day ...
... , SAN FRANCISCO, Aug. 14 While natural ... higher than 50 percent and none have been clinically proven to regulate ... e alth International (NHI), a vertically integrated San ... line has been clinically proven to alleviate symptoms of menopause in ...
... minimize the risk as fall looms, experts say , FRIDAY, ... year have another worry besides homework and lunchroom bullies: swine ... early and vigorously to reduce their risk of contracting the ... is going to strike the school-age child and it,s primarily ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , , KENILWORTH, N.J., Aug. ... announced that the U.S. Food and Drug Administration (FDA) has ... in adults and acute treatment of manic or mixed episodes ... in adults. SAPHRIS can be used as a first-line treatment ...
... , NEW YORK, Aug. 14 MS -- ... by AstraZeneca, found that while most patients with asthma understand ... accordingly. , , "This finding demonstrates ... and the necessary steps people should take to achieve better ...
Cached Medicine News:Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 2Health News:Biopelle, Inc. Acquires PRESCRIBEDsolutions [CUSTOMIZED SKINCARE](R) 3Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Get Smart About Swine Flu for Back-to-School 2Health News:Get Smart About Swine Flu for Back-to-School 3Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Keeping Asthma Under Control 2
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... company developing its Symphony® CGM System as a ... that Robert F. Doman , Executive Chairman ... at "TEN", Noble Financial Capital Markets, Tenth Annual ... make a corporate presentation to prospective corporate partners ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced that it expects revenues for ... $53 million, bringing expected full-year 2013 revenues to ... growth of 87% for 2013 above 2012 reflects ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: